Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1993-4-20
|
pubmed:abstractText |
Ninety-two patients in Colombia with cutaneous leishmaniasis were randomly assigned to groups to be treated with meglumine antimonate (infected control subjects; 10 mg of antimony/kg intramuscularly, twice a day for 20 days), pentamidine (2 mg/kg every other day intramuscularly, for a total of seven injections), or itraconazole (200 mg orally, twice a day for 28 days) or to receive no treatment (negative control subjects). In the group treated with meglumine antimonate, 21 of 23 patients healed by the first follow-up visit, 1.5 months after the end of therapy, and did not relapse (91% cure rate). In the pentamidine-treated group, 23 of 24 patients healed and did not relapse (96%). Four of the 23 pentamidine-treated patients who ultimately were cured had terminated therapy prematurely (after receiving 4-6 injections) because of hypotension (2 patients), hypoglycemia (1 patient), or headache and myalgias (1 patient). In a subsequent group of 19 patients who were administered 2 mg of pentamidine/kg every other day for a total of only four injections, 14 healed without relapse (74% cure rate). The itraconazole-treated group was similar to the no-treatment control group in terms of the number of patients for whom therapy failed (75% and 64%, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antifungal Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Itraconazole,
http://linkedlifedata.com/resource/pubmed/chemical/Ketoconazole,
http://linkedlifedata.com/resource/pubmed/chemical/Meglumine,
http://linkedlifedata.com/resource/pubmed/chemical/Pentamidine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1058-4838
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
16
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
417-25
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8384011-Administration, Oral,
pubmed-meshheading:8384011-Adolescent,
pubmed-meshheading:8384011-Adult,
pubmed-meshheading:8384011-Antifungal Agents,
pubmed-meshheading:8384011-Colombia,
pubmed-meshheading:8384011-Follow-Up Studies,
pubmed-meshheading:8384011-Humans,
pubmed-meshheading:8384011-Injections, Intramuscular,
pubmed-meshheading:8384011-Itraconazole,
pubmed-meshheading:8384011-Ketoconazole,
pubmed-meshheading:8384011-Leishmaniasis, Cutaneous,
pubmed-meshheading:8384011-Male,
pubmed-meshheading:8384011-Meglumine,
pubmed-meshheading:8384011-Pentamidine,
pubmed-meshheading:8384011-Treatment Outcome
|
pubmed:year |
1993
|
pubmed:articleTitle |
Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia.
|
pubmed:affiliation |
Bogota Military Hospital, Colombia.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|